JP2019530473A - プロインスリン誘導体 - Google Patents

プロインスリン誘導体 Download PDF

Info

Publication number
JP2019530473A
JP2019530473A JP2019533714A JP2019533714A JP2019530473A JP 2019530473 A JP2019530473 A JP 2019530473A JP 2019533714 A JP2019533714 A JP 2019533714A JP 2019533714 A JP2019533714 A JP 2019533714A JP 2019530473 A JP2019530473 A JP 2019530473A
Authority
JP
Japan
Prior art keywords
amino acid
peptide
insulin
compound according
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019533714A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019530473A5 (https=
Inventor
ディミトリオス ガトス
ディミトリオス ガトス
アレクサンドラ アナスタシウ
アレクサンドラ アナスタシウ
クレオメニス バルロス
クレオメニス バルロス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chemical and Biopharmaceutical Laboratories of Patras SA
Original Assignee
Chemical and Biopharmaceutical Laboratories of Patras SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemical and Biopharmaceutical Laboratories of Patras SA filed Critical Chemical and Biopharmaceutical Laboratories of Patras SA
Publication of JP2019530473A publication Critical patent/JP2019530473A/ja
Publication of JP2019530473A5 publication Critical patent/JP2019530473A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
JP2019533714A 2016-09-06 2017-09-05 プロインスリン誘導体 Pending JP2019530473A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GR20160100458 2016-09-06
GR20160100458 2016-09-06
PCT/IB2017/055336 WO2018047062A1 (en) 2016-09-06 2017-09-05 Proinsulin derivatives

Publications (2)

Publication Number Publication Date
JP2019530473A true JP2019530473A (ja) 2019-10-24
JP2019530473A5 JP2019530473A5 (https=) 2020-10-15

Family

ID=59895344

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019533714A Pending JP2019530473A (ja) 2016-09-06 2017-09-05 プロインスリン誘導体

Country Status (10)

Country Link
US (1) US11230585B2 (https=)
EP (1) EP3509625A1 (https=)
JP (1) JP2019530473A (https=)
KR (1) KR20190043609A (https=)
CN (1) CN110234339A (https=)
AU (1) AU2017322552B2 (https=)
BR (1) BR112019004314A2 (https=)
CA (1) CA3035850A1 (https=)
IL (1) IL265182A (https=)
WO (1) WO2018047062A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3756679A1 (en) 2019-06-28 2020-12-30 Université de Genève Compositions for use in the treatment of insulin deficiency conditions

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61221200A (ja) * 1985-03-22 1986-10-01 ノボ　ノルディスク　アクティーゼルスカブ インシュリンの製造方法
JPH05255392A (ja) * 1991-06-11 1993-10-05 Eli Lilly & Co Ａ−ｃ−ｂプロインスリン、その製造法および使用法、およびインスリン生産の中間体
JPH10511849A (ja) * 1994-12-29 1998-11-17 バイオ−テクノロジー・ジェネラル・コーポレーション ヒト・インスリンの生成
JP2001521004A (ja) * 1997-10-24 2001-11-06 イーライ・リリー・アンド・カンパニー 脂肪酸−アシル化インスリン類似体
WO2015083114A2 (en) * 2013-12-05 2015-06-11 Chemical & Biopharmaceutical Laboratories Of Patras S.A. Biologically active insulin derivatives

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK58285D0 (da) 1984-05-30 1985-02-08 Novo Industri As Peptider samt fremstilling og anvendelse deraf
DK10191D0 (da) 1991-01-22 1991-01-22 Novo Nordisk As Hidtil ukendte peptider
WO1995016708A1 (en) 1993-12-17 1995-06-22 Novo Nordisk A/S Proinsulin-like compounds
CN1231259C (zh) * 1994-12-29 2005-12-14 萨文特医药公司 生产人胰岛素
EP0741188A3 (en) 1995-05-05 1999-07-14 Eli Lilly And Company Single chain insulin with high bioactivity
US6444641B1 (en) 1997-10-24 2002-09-03 Eli Lilly Company Fatty acid-acylated insulin analogs
GB9812675D0 (en) 1998-06-11 1998-08-12 Univ Edinburgh Peptides
EP1193272B1 (en) 2000-10-02 2004-06-30 Yonsei University Single-chain insulin analogs
KR100449454B1 (ko) * 2000-10-02 2004-09-21 이현철 단일사슬 인슐린 유도체의 유전자를 포함하는 당뇨병치료용 벡터
WO2002079251A2 (en) * 2001-04-02 2002-10-10 Novo Nordisk A/S Method for making human insulin precursors
EP1692168B1 (en) 2003-12-03 2011-07-20 Novo Nordisk A/S Single-chain insulin
JP2008533100A (ja) 2005-03-18 2008-08-21 ノボ ノルディスク アクティーゼルスカブ Ｐｅｇ化された単鎖インスリン
US20090069216A1 (en) 2006-02-21 2009-03-12 Novo Nordisk A/S Single-Chain Insulin Analogues and Pharmaceutical Formulations Thereof
JP2009530243A (ja) 2006-03-13 2009-08-27 ノボ・ノルデイスク・エー／エス アシル化単鎖インスリン
WO2008043033A2 (en) 2006-10-04 2008-04-10 Case Western Reserve University Fibrillation-resistant insulin and insulin analogues
US10100098B2 (en) * 2006-12-13 2018-10-16 Stelis Biopharma Private Limited Insulin production methods and proinsulin constructs
GR1006941B (el) * 2009-06-01 2010-08-27 Χημικα Και Βιοφαρμακευτικα Εργαστηρια Πατρων Αε (Cbl-Patras), Πεπτιδικη συνθεση (peptide synthesis)
GR1007010B (el) 2009-10-08 2010-10-07 Χημικα Και Βιοφαρμακευτικα Εργαστηρια Πατρων Αε (Cbl-Patras), Ινσουλινοειδη πεπτιδια
US9982287B2 (en) * 2013-12-17 2018-05-29 Novo Nordisk A/S Enterokinase cleavable polypeptides

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61221200A (ja) * 1985-03-22 1986-10-01 ノボ　ノルディスク　アクティーゼルスカブ インシュリンの製造方法
JPH05255392A (ja) * 1991-06-11 1993-10-05 Eli Lilly & Co Ａ−ｃ−ｂプロインスリン、その製造法および使用法、およびインスリン生産の中間体
JPH10511849A (ja) * 1994-12-29 1998-11-17 バイオ−テクノロジー・ジェネラル・コーポレーション ヒト・インスリンの生成
JP2001521004A (ja) * 1997-10-24 2001-11-06 イーライ・リリー・アンド・カンパニー 脂肪酸−アシル化インスリン類似体
WO2015083114A2 (en) * 2013-12-05 2015-06-11 Chemical & Biopharmaceutical Laboratories Of Patras S.A. Biologically active insulin derivatives

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
RAJPAL, G. ET AL.: ""Single-chain insulins as receptor agonists"", MOL. ENDOCRINOL., vol. 23, JPN6021023450, 2009, pages 679 - 688, ISSN: 0004771783 *

Also Published As

Publication number Publication date
AU2017322552A1 (en) 2019-03-28
CN110234339A (zh) 2019-09-13
EP3509625A1 (en) 2019-07-17
KR20190043609A (ko) 2019-04-26
IL265182A (en) 2019-05-30
AU2017322552B2 (en) 2021-12-02
WO2018047062A1 (en) 2018-03-15
BR112019004314A2 (pt) 2019-05-28
CA3035850A1 (en) 2018-03-15
US20190263881A1 (en) 2019-08-29
US11230585B2 (en) 2022-01-25

Similar Documents

Publication Publication Date Title
KR102461744B1 (ko) 아미노 2산을 함유한 펩타이드 변형제
CA2875599C (en) Pegylated oxyntomodulin variants
KR102005385B1 (ko) 부위-특이적 모노-치환 페길화 엑센딘 유사체 및 그것의 제조방법
JP2007537141A (ja) 新規なｇｌｐ−１化合物
CN106164088B (zh) 长效肾上腺髓质素衍生物
US20220411461A1 (en) Methods of making incretin analogs
US11168114B2 (en) Process for the manufacture of degarelix and its intermediates
AU2016273045B2 (en) Pegylated oxyntomodulin variants
EP3360884A1 (en) Improved process for the preparation of a dodecapeptide
AU2017248496B2 (en) Biologically active insulin derivatives
US11230585B2 (en) Proinsulin derivatives
CA2931439C (en) Biologically active insulin derivatives
JP2023541138A (ja) ペプチド及びタンパク質の誘導体化

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200907

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200907

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210616

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210621

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210806

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211117

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220404

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220516

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220812

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221011

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230123